India, July 23 -- Biocon Ltd announced on Wednesday that its subsidiary, Biocon Biologics, has launched a new treatment for autoimmune diseases such as rheumatoid arthritis in the Australian market.
In a regulatory filing, the company stated that it has introduced Nepexto, a biosimilar of the reference drug Enbrel (Etanercept), in Australia. The product will be marketed in collaboration with Generic Health, a leading Australian provider of high-quality generic, injectable, and over-the-counter medicines.
Through this partnership, Biocon Biologics aims to enhance patient access to advanced therapies for autoimmune conditions in Australia.
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....